Drug Repurposing for Rabies Treatment: A Computational Analysis of 14 Agents

10 January 2024, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


This study explores the repurposing potential of 14 drugs (Emtricitabine, Famciclovir, Acyclovir, Stavudine, Cidofovir, Tinidazole, Ribavirin, Valaciclovir, Nevirapine, Atazanavir, Rilpivirine, Dasabuvir, Raltegravir, Elvitegravir) against the rabies virus glycoprotein pre-fusion trimer complexed with neutralizing antibody RVA122. Using docking and NAMD simulations, a drug ranking system considers key properties (docking score, hepatotoxicity, micro nuclear testing, human intestinal absorption, bioavailability, and blood-brain barrier (BBB) permeability). Excluding drugs with negative BBB (Atazanavir, Rilpivirine, Raltegravir, Elvitegravir), the top five candidates are Emtricitabine, Famciclovir, Acyclovir, Stavudine, and Cidofovir, showing promise for rabies treatment. In vitro and in vivo analyses are imperative for comprehensive validation, including drugs with negative BBB, as alternative mechanisms may contribute to therapeutic efficacy. This approach offers a cost-effective strategy for potential rabies treatment.


Rabies treatment
Drugs Repurposing
Molecular Dynamic Simulation
Molecular Docking


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.